Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 GeneticVariation disease BEFREE Amplification of the c-erbB-2 protooncogene has been associated with a poor prognosis in human breast and ovarian cancers. 1679963 1991
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE However, the role of HER-2 in the development of ovarian cancer has not been sufficiently elucidated. 23292493 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease CTD_human Trastuzumab (Herceptin) targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-30% of breast and ovarian cancers carrying a bad prognosis. 19896266 2010
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE Overexpression of erbB-2 plays a key role in tumorigenesis or progression such as breast cancer and ovarian cancer. 19242112 2009
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE HER-2 oncogene encodes a transmembrane growth factor receptor that is overexpressed in 25-30% of patients with primary breast and ovarian cancer. 9811454 1998
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE HER2/neu is known to be overexpressed in approximately 40% of human breast and ovarian cancers and it is associated with increased metastasis and poor prognosis. 11821047 2002
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Adenovirus-type 5 E1a gene can efficaciously inhibit HER-2/neu-overexpressing ovarian cancer, and this promising procedure could greatly benefit ovarian cancer patients with high expression of HER-2/neu. 11285029 2001
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer. 20003286 2009
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE Overexpression of the HER-2/neu oncogene is present in approximately one third of ovarian cancers and is associated with poor prognosis. 8634990 1995
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE Previous reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. 7685420 1993
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Expressions of nm23 gene products/nucleoside diphosphate kinases, epidermal growth factor receptor, erbB-2 protein, and sex steroid receptor status in ovarian carcinomas were also examined by immunohistochemistry. 7907945 1994
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 GeneticVariation disease BEFREE In breast and ovarian cancers, the ErbB2 growth factor receptor is overexpressed and this contributes to the progression of these cancers, in part by constitutively activating survival signaling pathways. 15032666 2004
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins. 26436696 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE Overexpression of the HER2/neu oncogene is a frequent molecular event in multiple human cancers including breast and ovarian cancer. 11706403 2001
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE Aberrant <i>EGFR</i> expression and <i>ERBB2/3/4</i> mRNA levels were associated with OC prognosis. 30588099 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Immunohistochemical evaluation of ErbB-2 protein and RT-PCR for survivin were also performed. dMTase was positive in 88.4% of ovarian cancers but only in 9.3% of non-cancerous ovaries (P<0.001, Fisher's exact test). 11431104 2001
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Forty-five patients with stage III or IV HER-2/neu overexpressing breast or ovarian cancer were evaluated for HER-2/neu specific T cell and antibody immunity. 11072789 2000
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE The HER2 oncogene and its relative oncoprotein, gp185HER2, a transmembrane glycoprotein belonging to the epidermal growth factor receptor family, are overexpressed in a wide range of solid tumors including breast and ovarian cancer. 11394499 2001
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Overexpression of the receptor tyrosine kinase HER-2/neu is associated with poor prognosis in patients with breast and ovarian cancer. 14612517 2003
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE The aim of this study was to investigate the potential prognostic value of SKP2, genes P27Kip1, K-ras, c-Myc, COX2 and HER2 genes expression in ovarian cancer. 26320455 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE HER-2/neu is a proto-oncogene associated with poor prognosis in women with breast and ovarian carcinoma. 10202671 1999
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease CTD_human Eight of 10 RCC cell lines expressed significant levels of HER-2/neu mRNA and protein, but at a lower level compared with HER-2/neu overexpressing ovarian carcinoma cells. 10897039 2000
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE These data suggest that trastuzumab in combination with pertuzumab could be an effective approach in high HER2-expressing ovarian cancers and could also enhance sensitivity to endocrine therapy in ERα-positive ovarian cancer. 21571868 2011
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE These data suggest that amplification of the C-erbB-2 gene may play a role in the pathogenesis of ovarian carcinoma; it is frequently observed in advanced ovarian cancer and is associated with poor prognosis for these patients. 7805442 1994
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE Here, we have identified a molecular link between FAS and HER2 (erbB-2) oncogene, a marker for poor prognosis that is overexpressed in 30% of breast and ovarian cancers. 15235125 2004